# Bone Metastases and Skeletal-Related Events

> Bone metastases and skeletal-related events for NEET-PG Medicine, covering osteolytic and sclerotic primaries, bone-modifying agents and radiotherapy choices.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/bone-metastases-and-skeletal-related-events
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: Harrison's Principles of Internal Medicine; Oxford Handbook of Oncology
- How to cite: "Bone Metastases and Skeletal-Related Events", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/bone-metastases-and-skeletal-related-events

## Direct answer

Bone metastases are secondary deposits in the skeleton, most often from breast, prostate, lung, kidney and thyroid cancers. Skeletal-related events are pathological fracture, spinal cord compression and need for bone radiotherapy or surgery, with hypercalcaemia counted in some definitions. Osteolytic lesions are typical of kidney, lung and thyroid primaries, prostate cancer usually gives sclerotic deposits, and bisphosphonates or denosumab reduce skeletal events.

## What you must remember

- **Common primaries:** breast, prostate, lung, kidney and thyroid cancers account for most skeletal metastases.
- **Osteolytic pattern:** kidney, lung, thyroid and some breast primaries destroy bone, and hypercalcaemia is a frequent accompaniment.
- **Sclerotic pattern:** prostate cancer predominantly, with some breast and carcinoid deposits adding bone density.
- **Skeletal-related events:** pathological fracture, spinal cord compression, need for radiotherapy or surgery to bone, and hypercalcaemia.
- **Bone-modifying agents:** bisphosphonates such as zoledronic acid and pamidronate, and the RANKL inhibitor denosumab, reduce skeletal events.
- **Bisphosphonate adverse effects:** osteonecrosis of the jaw, hypocalcaemia and an acute phase reaction after the first infusion.
- **Radiotherapy:** a single fraction of 8 Gy is standard for painful, uncomplicated bone metastases.

## Choosing a bone-directed treatment by lesion and risk

Bone metastases are managed by first excluding emergencies, then mapping the disease and choosing a treatment for pain, fracture risk and future events. The steps below follow that order.

1. **Recognise the emergency first.** Cord compression, severe hypercalcaemia or an impending fracture is assessed before anything else.
2. **Image the whole skeleton.** A bone scan, CT or MRI maps the lesions, and MRI is preferred for spinal disease.
3. **Identify the pattern.** An osteolytic or sclerotic pattern narrows the likely primary and guides the rest of the workup.
4. **Assess fracture risk.** Lesions in weight-bearing bones, such as the femur, are scored with a tool such as the Mirels score to decide on prophylactic fixation.
5. **Treat pain with radiotherapy.** Single-fraction radiotherapy relieves painful lesions, and more complex or larger lesions need multi-fraction or specialised schedules.
6. **Start bone-modifying therapy.** Bisphosphonates or denosumab are used to reduce future skeletal events, with calcium and vitamin D status checked and a dental review before starting.

## Where the exam tries to catch you

Questions test whether bone-modifying drugs are matched to their purpose, not used for pain or emergencies alone.

- **Trap:** Bisphosphonates are given to treat the pain of a bone deposit. **Correct:** they reduce skeletal events and hypercalcaemia, but painful lesions still need radiotherapy or analgesia.
- **Trap:** A painful vertebral metastasis is managed with radiotherapy alone. **Correct:** a neurological deficit or spinal instability calls for urgent decompression surgery and radiotherapy.
- **Trap:** Denosumab is the first drug for acute hypercalcaemia. **Correct:** intravenous fluids and zoledronic acid come first, and denosumab is reserved for refractory or bisphosphonate-resistant cases.

## Frequently asked questions

### Which primary cancers commonly metastasise to bone?

Breast, prostate, lung, kidney and thyroid cancers are the commonest primaries producing bone metastases. Prostate cancer typically gives sclerotic deposits, while kidney and thyroid cancers usually cause osteolytic lesions.

### What is the difference between osteolytic and sclerotic bone metastases?

Osteolytic metastases destroy bone and are typical of kidney, lung and thyroid primaries, whereas sclerotic metastases add bone density and are typical of prostate cancer. The pattern narrows the likely primary and helps guide the workup.

### What adverse effect of bisphosphonates is most often tested?

Osteonecrosis of the jaw is the adverse effect most often tested with bisphosphonates such as zoledronic acid. The risk is higher after dental extraction, so a dental review is advised before bone-modifying therapy starts.

### Which radiotherapy schedule is standard for painful bone metastases?

A single fraction of 8 Gy is a standard schedule for painful, uncomplicated bone metastases, and it gives effective pain relief. Multi-fraction schedules are used for larger or more complex lesions where more coverage is needed.

### How is spinal cord compression from bone metastases managed?

Spinal cord compression from bone metastases is an oncological emergency, managed with high-dose corticosteroids and urgent MRI of the spine. Decompressive surgery or radiotherapy follows, depending on neurological status and spinal stability.